Pagination
- Previous page
- Page 67
Social

Consistent data that antimalarials did NOT decrease hospitalization for viral infections in the pre #COVID19 era in US claims database in SLE &RA pts #0002 @RheumNow @CRASCRRheum #ACR20 #ACR2020 https://t.co/nZp5dOeHXB
Janet Pope @Janetbirdope ( View Tweet )
4 years 5 months ago

#COVID19 outcomes in systematic autoimmune diseases N=716 Pop’n matched by age & sex other COVID pts. Glass is half empty. More hospitalization, ICU, ventilation but death 5% v 4.3%. Abstr#430 #ACR20 @RheumNow @CRASCRRheum https://t.co/cqko0Igd8L
Janet Pope @Janetbirdope ( View Tweet )
4 years 5 months ago

Should we in rheumatology be the ones leading the trials using our drugs with checkpoint inhibitors?
Can we learn lessons about collaborative work from @rheum_covid?
Provoking questions for the new challenges in treatment of irAEs! https://t.co/chl8TeOoMy
David Liew @drdavidliew ( View Tweet )
4 years 5 months ago

Great talk by @rheumcat @rheum_covid on COVID-19 impact on rheumatology. Talk to pts re: what to do with rheum rx... they haven't read guidelines and may make their own changes! Prepare them for exposure/ifn! #ACR20 @Rheumnow 2F042 https://t.co/HkxbkYjEm3
Eric Dein @ejdein1 ( View Tweet )
4 years 5 months ago

Another study on rheum pt outcomes w/#COVID19: similar outcomes as nonrheum pts. MGH/JHU/Brigham 143 rheum vs 688 nonrheum. No⬆️risk in rheums after adjusting for race/smoking/comorbidities for: hospitalizations, mech ventil'n 3. ICU 4. death #ACR20 Abstr#L01 @RheumNow https://t.co/362UZUe5dg
k dao @KDAO2011 ( View Tweet )
4 years 5 months ago

Dr. Phillips touches on a few things to consider how teleheath has changed the delivery of care due to COVID-19. Planning your post-pandemic business strategy, due demand for our specialty, is important. #ACR20 @RheumNow https://t.co/A2dsVy1KSg
Dr. Rachel Tate @uptoTate ( View Tweet )
4 years 5 months ago

Highlighting results from @rheum_covid at #ACR20
Race/ethnicity Associated with Poor Outcomes in #RheumaticDisease Patients with #COVID19 by @MilenaGianfran et al
Abstract #0006👉https://t.co/13jsl8BjcH
Full paper👉https://t.co/Qeo0dOoIOQ
@RheumNow
https://t.co/U9cgaYYaOj
Links:
Mrinalini Dey @DrMiniDey ( View Tweet )
4 years 5 months ago

#ACR20 keynote Infectious disease Dr Eric Rubin @NEJM EIC answers questions about medications, immunity and vaccines in #COVID19. Many post covid inflammatory symptoms but not sure if its because of background autoimmunity. Need more data. More to come in a few months @RheumNow
Bella Mehta @bella_mehta ( View Tweet )
4 years 5 months ago

Eric Rubin, MD, editor-in-chief @NEJM #ACR20 discusses how New Zealand can have large rugby matches by intervening before infection occurs. #LTF, @RheumNow.
Eric Dein @ejdein1 ( View Tweet )
4 years 5 months ago

Reminder of the glucocorticoids (GC) paradigm: don’t use them early during viral replication as morbidity and mortality (M&M) can increase with early use! But GCs CAN prevent the late complications that cause M&M when used at the appropriate time point. #ACR20 @RheumNow https://t.co/l2e0J1nANd
Meral K. El Ramahi, MD @MeralElRamahiMD ( View Tweet )
4 years 5 months ago